RE:RE:RE:"The reality is the boats are shaking" January 09, 2024 - JPM 24 - Merck wants to beef up its immunology pipeline through additional deals, the Big Pharma’s chief medical officer Eliav Barr said at an Endpoints News event on Tuesday.
“We’ll be looking for those immunology opportunities that we think can complement or add a new facet to things,” Barr said.
In April 2023 Merck acquired the precision medicine Phase 2 clinical stage biopharma company Prometheus Biosciences for USD$10.8 Billion.